Recent changes
- Aug 7, 2026Aug 7, 2026BlossomHill Prices Upsized $150M IPO, Debuts on Nasdaq Pulse story
- Aug 3, 2026Aug 3, 2026BlossomHill Files for $100M Nasdaq IPO in Cancer Drugs Pulse story
Latest Pulse
- Aug 10, 2026Biotech IPO Window Closes Its Strongest Week Since SpringBlossomHill and Latigo Biotherapeutics both closed upsized IPOs by August 10, capping a four-deal stretch that also included Braveheart Bio and Attovia Therapeutics pricing above or near the top of their ranges.→
- Aug 10, 2026Attovia Therapeutics Climbs 29% After $289M IPOAttovia Therapeutics priced an upsized $289 million IPO and climbed 29% on debut, the fourth biotech in two weeks to price well above its original terms.→
- Aug 8, 2026Biotech IPOs Are Pricing Above Range AgainBlossomHill and Braveheart Bio both upsized and priced above their original ranges this week, the clearest two-deal signal yet that the biotech IPO window -- closed to all but the strongest names in 2024-2025 -- is reopening.→
- Aug 7, 2026Latigo Biotherapeutics Jumps 17% in $345.6M IPOLatigo Biotherapeutics priced its upsized IPO at $18 a share for $345.6 million and jumped 17% in its Nasdaq debut, the third biotech offering in two weeks to price above range.→
- Aug 7, 2026BlossomHill Prices Upsized $150M IPO, Debuts on NasdaqBlossomHill Therapeutics priced an upsized IPO at $16 a share for $150M and began trading on Nasdaq under BLSM, more than 50% above the $100M target Pulse flagged when the company first filed.→
- Aug 3, 2026BlossomHill Files for $100M Nasdaq IPO in Cancer DrugsBlossomHill Therapeutics filed for a $100M Nasdaq IPO under ticker BLSM, adding an oncology-focused biotech with $257M in prior funding to a summer pipeline of clinical-stage listings led by J.P. Morgan, Leerink and Guggenheim.→
- Jul 16, 2026Seven Companies File S-1s in a Single WeekSeven companies spanning biotech, fintech, AI and battery materials filed IPO registration paperwork with the SEC within days of each other, a broad-based cluster that extends the sustained widening of 2026's listing pipeline.→
Coverage Timeline
newest firstAll Coverage
IPO~$972M, 4 deals
Biotech IPO Window Closes Its Strongest Week Since Spring
BlossomHill and Latigo Biotherapeutics both closed upsized IPOs by August 10, capping a four-deal stretch that also included Braveheart Bio and Attovia Therapeutics pricing above or near the top of their ranges.
FOLLOW-UP
Biotech IPOs Are Pricing Above Range Again
IPO$532.5M combined
Biotech IPOs Are Pricing Above Range Again
BlossomHill and Braveheart Bio both upsized and priced above their original ranges this week, the clearest two-deal signal yet that the biotech IPO window -- closed to all but the strongest names in 2024-2025 -- is reopening.
BY THE NUMBERS